JP2024086870A5 - - Google Patents

Download PDF

Info

Publication number
JP2024086870A5
JP2024086870A5 JP2024063938A JP2024063938A JP2024086870A5 JP 2024086870 A5 JP2024086870 A5 JP 2024086870A5 JP 2024063938 A JP2024063938 A JP 2024063938A JP 2024063938 A JP2024063938 A JP 2024063938A JP 2024086870 A5 JP2024086870 A5 JP 2024086870A5
Authority
JP
Japan
Prior art keywords
composition
cdr
engineered
tregs
scfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024063938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024086870A (ja
JP7697096B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/023395 external-priority patent/WO2019190879A1/en
Application filed filed Critical
Publication of JP2024086870A publication Critical patent/JP2024086870A/ja
Publication of JP2024086870A5 publication Critical patent/JP2024086870A5/ja
Priority to JP2025097962A priority Critical patent/JP2025123315A/ja
Application granted granted Critical
Publication of JP7697096B2 publication Critical patent/JP7697096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024063938A 2018-03-27 2024-04-11 神経変性疾患を処置するためのCAR-Tregベースの治療 Active JP7697096B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025097962A JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのCAR-Tregベースの治療

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862648684P 2018-03-27 2018-03-27
US62/648,684 2018-03-27
PCT/US2019/023395 WO2019190879A1 (en) 2018-03-27 2019-03-21 Car-treg-based therapies for treating neurodegenerative diseases
JP2021502704A JP2021531280A (ja) 2018-03-27 2019-03-21 神経変性疾患を処置するためのCAR−Tregベースの治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021502704A Division JP2021531280A (ja) 2018-03-27 2019-03-21 神経変性疾患を処置するためのCAR−Tregベースの治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025097962A Division JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのCAR-Tregベースの治療

Publications (3)

Publication Number Publication Date
JP2024086870A JP2024086870A (ja) 2024-06-28
JP2024086870A5 true JP2024086870A5 (https=) 2024-10-25
JP7697096B2 JP7697096B2 (ja) 2025-06-23

Family

ID=68060734

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021502704A Pending JP2021531280A (ja) 2018-03-27 2019-03-21 神経変性疾患を処置するためのCAR−Tregベースの治療
JP2024063938A Active JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのCAR-Tregベースの治療
JP2025097962A Pending JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのCAR-Tregベースの治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021502704A Pending JP2021531280A (ja) 2018-03-27 2019-03-21 神経変性疾患を処置するためのCAR−Tregベースの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025097962A Pending JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのCAR-Tregベースの治療

Country Status (7)

Country Link
US (2) US12173030B2 (https=)
EP (1) EP3773629A4 (https=)
JP (3) JP2021531280A (https=)
KR (2) KR20250174989A (https=)
CN (1) CN112867496B (https=)
AU (1) AU2019242381B2 (https=)
WO (1) WO2019190879A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773629A4 (en) 2018-03-27 2022-01-19 AZTherapies, Inc. CAR-TREG-BASED THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CN116134144A (zh) 2020-04-23 2023-05-16 Az治疗股份有限公司 细胞的hla-i类mhc消融
EP4157877A2 (en) * 2020-05-28 2023-04-05 AZTherapies, Inc. Car-treg-based therapies targeting myelin oligodendrocyte glycoprotein (mog) for treating neurodegenerative diseases
EP4396216A1 (en) * 2021-09-03 2024-07-10 Sangamo Therapeutics, Inc. Mog-binding proteins and uses thereof
TW202321286A (zh) * 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
CN118272314A (zh) * 2024-04-15 2024-07-02 华中科技大学同济医学院附属同济医院 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140971A2 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Cell adhesion proteins as biomarker for alzheimer's disease
US20080027001A1 (en) * 2006-07-07 2008-01-31 Andrew Wood Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
EP2673300B1 (en) * 2011-02-11 2016-08-24 Memorial Sloan-Kettering Cancer Center Hla-restricted, peptide-specific antigen binding proteins
US20140348808A1 (en) * 2011-05-19 2014-11-27 Olga De La Rosa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
SG11201705401YA (en) * 2014-12-30 2017-08-30 The Brigham And Women`S Hospital Inc Methods to improve cell therapy
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
SI3280441T1 (sl) * 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
JP7123794B2 (ja) 2015-12-09 2022-08-23 メモリアル スローン ケタリング キャンサー センター 免疫細胞組成物及びそれを使用する方法
KR102585074B1 (ko) * 2017-11-11 2023-10-04 마이크로머티어리얼즈 엘엘씨 고압 프로세싱 챔버를 위한 가스 전달 시스템
EP3773629A4 (en) 2018-03-27 2022-01-19 AZTherapies, Inc. CAR-TREG-BASED THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP4157877A2 (en) * 2020-05-28 2023-04-05 AZTherapies, Inc. Car-treg-based therapies targeting myelin oligodendrocyte glycoprotein (mog) for treating neurodegenerative diseases

Similar Documents

Publication Publication Date Title
JP2024086870A5 (https=)
JP2024167313A5 (https=)
JP2024056687A5 (https=)
JP2021501162A5 (https=)
JP2017052784A5 (https=)
JP2021514973A5 (https=)
JP2023123726A5 (https=)
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JP2023134618A5 (https=)
JP2009225799A5 (https=)
RU2008149918A (ru) Антитела к nkg2a и их применения
RU2018146050A (ru) Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген
RU2018146158A (ru) Антитела
JP2020037555A5 (https=)
JP2023504016A5 (https=)
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2011509245A5 (https=)
HRP20241013T1 (hr) Protutijela za kelatirane radionuklide
RU2017121327A (ru) Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
JP2021533159A5 (https=)
JP2016505546A5 (https=)
JP2021094022A5 (https=)
JP2022512234A5 (https=)
JP2021520832A5 (https=)
JP2022513043A5 (https=)